Over 450 Total Lots Up For Auction at Three Locations - CO 05/12, PA 05/15, NY 05/20

IBA Dosimetry to showcase DOLPHIN advancements enabling verification of the complete RT treatment chain

Press releases may be edited for formatting or style | April 19, 2018 Rad Oncology Proton Therapy Radiation Therapy



***ends***

stats
DOTmed text ad

We repair MRI Coils, RF amplifiers, Gradient Amplifiers and Injectors.

MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013

stats

About the DOLPHIN ® System
Dolphin is a complete solution to detect and verify possible treatment dose discrepancies, thus contributing to a more efficient and safer radiation therapy. This improvement is based on DOLPHIN‘s high treatment dose measurement resolution. Highly complex IMRT and rotational treatment plans are delivered and measured with the DOLPHIN transmission detector prior to each patient treatment. A sophisticated TPS-Class software allows verification of dose deviations in 3D patient anatomy between the plan and actual delivered dose measured with DOLPHIN. The DOLPHIN solution including the detector and the software is “online ready” and currently used for pre-treatment QA. The system will be capable of measuring the actual patient treatment dose in online mode, fraction by fraction. The online capability is currently pending release.

About IBA Dosimetry
IBA Dosimetry GmbH innovates radiation therapy, proton therapy and diagnostic imaging through integrated Quality Assurance solutions that are efficient, intuitive and that provide peace of mind for healthcare professionals and patients around the world. The myQA® Global QA Platform is the backbone for Integrated Quality Assurance solutions. IBA Dosimetry has more than 220 international employees in four offices in Germany, France, China and USA.

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Back to HCB News

You Must Be Logged In To Post A Comment